AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

SINGH RAMAN sold $1.2M of LQDA

SINGH RAMAN sold 17,492 shares of Liquidia Corp (LQDA) at an average of $67.43 ($66.16–$68.62, $1.18M total) across 2 trades over 2026-09-11 to 2026-09-14.

Original reporting
SEC EDGAR · SINGH RAMAN
Published Sep 15, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, a primary source filing.

02

Market read

First‑report insider sale; modest materiality for a micro‑cap, may influence short‑term price.

03

What to watch

Company's recent pipeline developments could offset concerns from the sale.

Relevance 6/10Novelty 7/10Timing: Filed Sep 15, 2026 (post‑market)

Background

Liquidia Corp (NASDAQ:LQDA) is a biotech firm developing drug delivery platforms.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Director Singh Raman sold 17,492 shares for $1.18M, reducing his stake to 44,637 shares.

Expected impact

Modest short-term dip, potential 1-2% decline.

Evidence & confidence

Sale size is material for a micro‑cap, but no 10b5‑1 plan and insider remains a significant holder.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

No broader regional effect.

Global

Limited to investors tracking micro‑cap biotech stocks.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily indicate negative outlook.

Key entities

  • Director
    Singh Raman

    Director of Liquidia Corp who sold shares.

  • Company
    Liquidia Corp

    Biotech company subject of the Form 4 filing.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com